Anhui Medical University, Hefei, P. R. China.
Am J Chin Med. 2010;38(4):713-25. doi: 10.1142/S0192415X10008184.
This study was initiated to determine the possible antidiabetic effects of total flavonoids of Litsea Coreana leve (TFLC), an alcohol extract from the dried leaves of Litsea Coreana leve, on type 2 diabetic rats. Male Sprague-Dawley rats (n = 40, 160-180 g) were divided into two groups and fed with normal chow diet (Normal Control group) or high-fat diet (HFD) for a period of 4 weeks. After 4 weeks of dietary manipulation, the HFD-fed rats were injected with 30 mg/kg streptozocin (STZ) to induce diabetes 72 hours after STZ injection. These diabetic rats were randomly divided into 3 groups (n = 10): Diabetic Control group, Diabetic + TFLC group and Diabetic + PIO group. Diabetic + TFLC group and Diabetic + PIO group were orally administered with 400 mg/kg TFLC or 10 mg/kg pioglitazone (all suspended in 0.5% CMC-Na) respectively for 6 weeks. All rats were examined for body weight, serum and hepatic biochemical indices, content of malondialdehyde (MDA), activities of superoxide dismutase (SOD) and pathological changes in liver and pancreas, as well as protein tyrosine phosphatase 1B (PTP1B) expression in liver. The diabetic rats became obese, insulin resistant, hyperglycemic and hyperlipidemic. Treatment with TFLC showed a significant increase in insulin sensitivity, serum HDL-C level and SOD activities, meanwhile marked decrease in body weight, serum FFA, TC, TG, LDL-C, CRP, MDA content. TFLC also attenuated pathologic alterations in liver and pancreatic islet. Furthermore, TFLC was found to decrease the expression of PTP1B in diabetic rat liver. These results suggested that TFLC could ameliorate hyperglycemia, hyperlipoidemia, inflammation and oxidation stress, as well as insulin resistance of type 2 diabetic rats.
本研究旨在探讨从山鸡椒叶中提取的总黄酮(TFLC)对 2 型糖尿病大鼠的可能的抗糖尿病作用。雄性 Sprague-Dawley 大鼠(n = 40,160-180 g)分为两组,分别给予正常饲料(正常对照组)或高脂饲料(HFD)喂养 4 周。在饮食处理 4 周后,HFD 喂养的大鼠在 STZ 注射后 72 小时注射 30 mg/kg STZ 诱导糖尿病。这些糖尿病大鼠随机分为 3 组(n = 10):糖尿病对照组、糖尿病+TFLC 组和糖尿病+PIO 组。糖尿病+TFLC 组和糖尿病+PIO 组分别给予 400 mg/kg TFLC 或 10 mg/kg 吡格列酮(均悬浮于 0.5% CMC-Na)灌胃 6 周。所有大鼠均检测体重、血清和肝生化指标、丙二醛(MDA)含量、超氧化物歧化酶(SOD)活性以及肝、胰腺的病理变化,同时检测肝组织蛋白酪氨酸磷酸酶 1B(PTP1B)的表达。糖尿病大鼠表现出肥胖、胰岛素抵抗、高血糖和高血脂。TFLC 治疗可显著提高胰岛素敏感性、血清高密度脂蛋白胆固醇(HDL-C)水平和 SOD 活性,同时显著降低体重、血清游离脂肪酸(FFA)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、C 反应蛋白(CRP)、MDA 含量。TFLC 还可减轻肝和胰腺胰岛的病理改变。此外,TFLC 可降低糖尿病大鼠肝组织中 PTP1B 的表达。这些结果表明,TFLC 可改善 2 型糖尿病大鼠的高血糖、高血脂、炎症和氧化应激以及胰岛素抵抗。